NVP-BVU972 NEW
| Price | $40 | $113 | $163 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: NVP-BVU972 | CAS No.: 1185763-69-2 |
| Purity: 98.61% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | NVP-BVU972 |
| Description | NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM. |
| Cell Research | BaF3 cells containing TPR-MET or various mutants thereof are grown in RPMI 1640 medium containing 10% fetal calf serum. For maintenance of parental BaF3 cells the medium is additionally supplemented with 10 ng/mL interleukin-3 (IL-3). For proliferation assays, BaF3 cells are seeded on 96-well-plates in triplicates at 104 cells per well and incubated with various concentrations of NVP-BVU972 for 72 hours followed by quantification of viable cells using a resazurin sodium salt dye reduction readout. IC50 values are determined with the XLFit Excel Add-In using a 4-parameter dose response model.(Only for Reference) |
| Kinase Assay | TR-FRET biochemical assay with MET wild type and mutants: Enzyme activity is measured in a time resolved fluorescence resonance energy transfer (TR-FRET) assay, detecting tyrosine phosphorylation with a Eu-labelled anti-phospho-tyrosine antibody (fluorescence donor) and Allophycocyanin conjugated to Streptavidin (fluorescence acceptor) which binds to a biotin on the substrate peptide. For each variant, Km concentrations for ATP are determined in the absence of NVP-BVU972, and the ATP concentration in the kinase reaction is set to Km (4 μM for MET wt, 1 μM for MET Y1230H and MET F1200I). NVP-BVU972 is dissolved and diluted in DMSO and assayed in quadruplicate. Kinase reactions are carried out in 50 mM Tris-HCl pH 7.5, 8 mM MgCl2, 4 mM MnCl2, 0.05 % Tween 20, 0.05% bovine serum albumin, 0.1 mM EDTA, 1 mM DTT, 0.1 mM Na3VO4, in white 1536 well plates at room temperature. NVP-BVU972 and enzyme are incubated in a volume of 2 μL for 20 min, followed by the addition of 1 μL ATP and 1 μL biotinylated peptide substrate (PTK1) to final concentrations of Km and 1 μM, respectively. Enzyme concentrations in the reactions are 5 nM for MET wt, and 4 nM for the F1200I and Y1230H variants. After 90 min, reactions are stopped by addition of 1 μL stop/detection solution to reach final concentrations of 10 mM EDTA, 3.5 nM Eu-labelled antiphospho-tyrosine antibody PY20, and 10 nM Streptavidin Allophycocyanin. Time resolved fluorescence resonance energy transfer is measured in an Envision plate reader (excitation 320 nm, emission 615 nm and 665 nm). |
| In vivo | NVP-BVU972 effectively inhibited the growth of MET gene-dispersed cell lines GTL-16, MKN-45, and EBC-1 with IC50 of 66, 82, and 32 nM, respectively.NVP-BVU972 effectively inhibited the MET kinase, while the inhibition of other kinases (including the most closely related ones), RON, was very low, with an IC50 of >1000 nM.NVP-BVU972 inhibited GTL-16, MKN-45 and EBC-1 with IC50 of >1000 nM.NVP-BVU972 inhibited GTL-16, MKN-45 and EBC-1 with IC50 of >1000 nM. BVU972 inhibited constitutive MET phosphorylation in GTL-16 cells and HGF-stimulated MET phosphorylation in A549 cells with IC50s of 7.3 and 22 nM, respectively.NVP-BVU972 acted on BaF3 cells expressing wild-type TPR-MET and dose-dependently decreased TPR-MET phosphorylation. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (132.21 mM), Sonication is recommended. Ethanol : 63 mg/mL (185.1 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) |
| Keywords | inhibit | NVP-BVU 972 | NVP-BVU972 | BaF3 TPR-MET | phosphorylation | cancer | BaF3 | c-Met/HGFR | anti-proliferation | MET resistance mutations | Inhibitor | NVP-BVU-972 | NVP BVU972 | NVPBVU972 |
| Inhibitors Related | Cabozantinib | Capmatinib 2HCl | SGI-7079 | (±)-Norcantharidin | L-Ascorbic acid 2-phosphate trisodium | Crizotinib | Amuvatinib | Norcantharidin | Cabozantinib S-malate | Capmatinib xHCl | Bacitracin Zinc | Capmatinib |
| Related Compound Libraries | Highly Selective Inhibitor Library | Anti-Colorectal Cancer Compound Library | Anti-Lung Cancer Compound Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Inhibitor Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1MG |
VIP1Y
|
Hubei Chuchang Biotech Co., Ltd.
|
2024-10-29 | |
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $40.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $1.00/1g |
VIP5Y
|
Career Henan Chemical Co
|
2020-01-10 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY